Science Current Events | Science News | Brightsurf.com
 
Email a Friend Send to a friend
Printer Friendly Print COX-2 Inhibitors Significantly Reduce Risk of Cancer

COX-2 Inhibitors Significantly Reduce Risk of Cancer

April 04, 2006

WASHINGTON, D.C. - Results from a new, five-year study show that regular use of popular prescription pain relievers may reduce the risk of breast cancer by up to 71 percent and may offer similar benefit in the prevention of prostate, colon and lung cancers.

The study findings were released today at the annual meeting of the American Association for Cancer Research in Washington, D.C.




"We believe this is the first study to show that selective COX-2 inhibitors have significant chemopreventive effects against breast cancer," says Dr. Randall Harris, professor and director of the Center for Molecular Epidemiology and Environmental Health in The Ohio State University College of Medicine and lead author of the study.

The results come from a larger, case-control study of NSAID use and its impact upon the four leading types of cancer in the United States: breast, lung, prostate and colon cancer. NSAIDs are non-steroidal, anti-inflammatory drugs that block the COX-2 enzyme pathway that is often activated in inflammation, cancer, heart disease and other disorders.

Harris and his colleagues studied the use of celecoxib (Celebrex), rofecoxib (Vioxx), regular aspirin, low-dose aspirin, ibuprofen and acetaminophen among 323 women with breast cancer from 1999-2004.

They compared the results with those from a control group of 649 cancer-free women matched for age, race and county of residence.

They discovered that women who used NSAIDs on a regular basis had less breast cancer. Specifically, they found that those who used celecoxib or rofecoxib for at least two years appeared to benefit the most, experiencing a 71 percent reduction in risk of breast cancer. Ibuprofen use over the same period was associated with a 64 percent reduction, while regular aspirin offered a 51 percent reduction in risk of the disease.

On the other hand, acetaminophen, which has a negligible effect upon COX-2 activity, and low-dose aspirin provided no significant change in the risk of breast cancer.

"The COX-2 signaling pathway is important in cancer because when it's activated, it can stimulate many key steps in cancer development, including cell division, inhibition of cell death, angiogenesis (the creation of new blood vessels to nourish growing tumors) and metastasis," says Harris, who is also a member of the OSU Comprehensive Cancer Center.

Harris says his research group is only midway through analyzing data from the other parts of the study, but adds that early results suggest that regular use of selective COX-2 inhibitors appears to provide about the same magnitude of protection from prostate, lung and colon cancer.

"These results suggest strong potential for regular use of these drugs in cancer prevention. Still, we know these drugs may have side effects, so we are not advising people to go out and start taking them until more studies confirm that they are safe and effective," says Harris.

Celebrex is still widely used for pain relief, but Vioxx was pulled off the market in 2004 following reports of heightened risk of heart attacks.

"It's clear that we need to have multiple retrospective and prospective studies to validate these findings," says Harris, who has been studying the impact of COX-2 inhibitors for many years. "Eventually, we may find that regular intake of a low dose of a COX-2 inhibitor may be enough to reset the COX-2 cascade and safely protect people against cancer."

Grants from Pfizer and the National Cancer Institute supported the study.

Study co-authors include Joanne Beebe-Donk and Galal Alshafie, both colleagues in the Center for Molecular Epidemiology and Environmental Health in the OSU College of Medicine.

The Ohio State University Medical Center



Related Cox-2 Inhibitors Current Events and Cox-2 Inhibitors News Articles Cox-2 Inhibitors Current Events and Cox-2 Inhibitors News RSS Cox-2 Inhibitors Current Events and Cox-2 Inhibitors News RSS
Is short-term Celecoxib intervention a effective method for preventing gastric carcinogenesis?
Since the isolation and culture of Helicobacter pylori (H. pylori) in 1983, this bacterium has become accepted as an important human pathogen for the development of gastritis, peptic ulcer, and gastric cancer.

Sensitizing tumor response to cancer therapy
Two forms of skin and brain cancer respond very poorly to chemotherapy and radiation: melanoma and glioblastoma multiforme brain cancer.

Potential Lung Disease Biomarkers Yield Clues to COX-2 Inhibitor Side Effects
In searching for a simple way to identify individuals with smoking-related lung injury, scientists at Weill Cornell Medical College have stumbled upon a potential explanation for why the class of pain-relievers known as COX-2 inhibitors increases the risk of heart problems among users.

USC researchers develop new drug to target tumor cells and blood vessels
Researchers at the University of Southern California have identified a new drug compound that appears to target tumor cells and surrounding blood vessels without the negative side effects typically associated with Cox-2 inhibitors.

Licorice compound offers new cancer prevention strategy
A chemical component of licorice may offer a new approach to preventing colorectal cancer without the adverse side effects of other preventive therapies, Vanderbilt University Medical Center researchers report.

Brain study may lead to improved epilepsy treatments
Using a rodent model of epilepsy, researchers found one of the body's own neurotransmitters released during seizures, glutamate, turns on a signaling pathway in the brain that increases production of a protein that could reduce medication entry into the brain.

Popular Arthritis Drug May Disrupt Heart Rhythm, UB Research Finds
Celebrex, a popular arthritis drug that blocks pain by inhibiting an enzyme known as COX-2, has been shown in laboratory studies to induce arrhythmia, or irregular beating of the heart, via a novel pathway unrelated to its COX-2 inhibition.

New study may explain Vioxx side effects
Vioxx and related pain medications were taken off the market in 2004 because they caused dangerous heart problems in some people.

COX-2 inhibitors delay pancreatic cancer precursors in mice
Nimesulide, a cyclooxygenase-2 (COX-2) inhibitor, delays the progression of precancerous pancreatic lesions in mice, according to researchers at David Geffen School of Medicine at UCLA.

Experimental gene therapy 'abolishes' arthritis pain and lessens joint damage
Early-stage research has found that a new gene therapy can nearly eliminate arthritis pain, and significantly reduce long-term damage to the affected joints, according to a study published today in the journal Arthritis and Rheumatism.
More Cox-2 Inhibitors Current Events and Cox-2 Inhibitors News Articles
Dollar Store

Dollar Store
Dr. Bob and the Cox-2 Inhibitors (Primary Contributor)



COX-2 Inhibitors (Milestones in Drug Therapy)

COX-2 Inhibitors (Milestones in Drug Therapy)
by Michel Pairet (Editor), Joanne van Ryn (Editor)

Reviews the chemical basis and the development of COX-2. Discusses future trends in further research and the roles of COX-1 and COX-2 in mucosal protection and ulcer healing. Features numerous halftone graphs, charts, and illustrations. For clinicians and researchers. DNLM: Anti-Inflammatory Agents, Non-Steroidal--therapeutic use.

Inflama-Rest COX-2 Inhibitor 90 tabs

Inflama-Rest COX-2 Inhibitor 90 tabs
by SOURCE NATURALS

Inflama-Rest is a Bio-Aligned formula that may ease joint function and support comfortable movement via inhibition of the COX-2 enzyme. It also addresses additional factors shown in scientific research to influence muscle and joint comfort: nuclear factor-kappa B activity, leukotriene regulation and nitric oxide production. Inflama-Rest helps to protect cells from free radical damage. It is specially formulated with adaptogenic herbs and minerals that may help reduce muscle tension associated with physical and emotional stress.



* Picture may be of different size or flavor

New Chapter Gingerforce, 30 Softgels, 0.35 Bottle

New Chapter Gingerforce, 30 Softgels, 0.35 Bottle
by New Chapter

Supports stomach, liver and intestinal health* Reduces inflammation* Contains certified organic herbal anti-aging constituents that inactivate free-radicals* Supports blood platelet health and cardiovascular function

  Small Talk
by Dr. Bob & the Cox-2 Inhibitors



Rolling Stone

Rolling Stone
Dr. Bob and the Cox-2 Inhibitors (Primary Contributor)



  COX-2 inhibitors intensify aspirin's gastric effects: even at low doses. (Gastroenterology).: An article from: Internal Medicine News
by Robert Finn (Author)

This digital document is an article from Internal Medicine News, published by International Medical News Group on April 1, 2003. The length of the article is 374 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser.

Citation Details
Title: COX-2 inhibitors intensify aspirin's gastric effects: even at low doses. (Gastroenterology).
Author: Robert Finn
Publication: Internal Medicine News (Magazine/Journal)
Date: April 1, 2003
Publisher: International Medical News Group
Volume: 36 Issue: 7 Page: 55(1)

Distributed by Thomson...

Green Blues

Green Blues
Dr. Bob and the Cox-2 Inhibitors (Primary Contributor)



Trends in Cox-2 Inhibitor Research

Trends in Cox-2 Inhibitor Research
by Maynard J. Howardell (Editor)

Cox-2 Inhibitors are newly developed drugs for inflammation that selectively block the Cox-2 enzyme. Blocking this enzyme impedes the production of the chemical messengers (prostaglandins) that cause the pain and swelling of arthritis inflammation. Cox-2 inhibitors are a new class of non-steroidal anti-inflammatory drugs (NSAIDS). Because they selectively block the Cox-2 enzyme and not the Cox-1 enzyme, these drugs are uniquely different from traditional NSAIDS. This book explores new research in the field.

Friendly

Friendly
Dr. Bob and the Cox-2 Inhibitors (Primary Contributor)



© 2009 BrightSurf.com